Fig. 1From: Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitorsInclusion, screening, and assignment of patients into groupsBack to article page